Press Releases

RenovoRx Announces Sixth U.S. Patent

TIGeR-PaC — a Phase III Clinical Trial Continues Enrolling Pancreatic Cancer Patients in the U.S. and Europe Los Altos, CA, June 9, 2020 – RenovoRx, an innovator in targeted cancer…
Read More

Contemporary Management of Pancreatic Cancer

An update on state-of-the-art minimally invasive therapies, including recent advances in surgery, radiation therapy, ablative options, and endovascular therapies. Reviews how recent advances in surgery, radiation therapy, ablative options, and…
Read More

Woman Receiving Experimental Treatments For Pancreatic Cancer At UPMC *

70-year old patient, Mrs. Darlene Bossolla, was diagnosed with inoperable pancreatic cancer last year. Now, part of the TIGeR-PaC clinical trial at UPMC with Dr. Paula Novelli, Mrs. Bossola is reporting her levels to be down and she is feeling great and that she believes this new procedure should be available to everyone.

Read More

New Cancer Procedure Gifts Bay Area Couple 3 More Years Together *

Based on results of early studies highlighted by this patient’s and other patients’ experiences, RenovoRx initiated and is currently enrolling Stage 3 pancreatic cancer patients in the TIGeR-PaC clinical trial to further test this promising new procedure for pancreatic cancer patients.

Read More

RenovoRx Begins Post-market Registry Study

RenovoRx has announced the opening of its post-market registry study, which will assess patient survival and clinical outcomes of the RenovoCath catheter when used to deliver gemcitabine and other chemotherapeutic…
Read More

RenovoRx Joins Stanford-Backed StartX Med Program

RenovoRx, a leading developer of innovative solutions for targeted delivery of therapeutics to selected sites in the peripheral vascular system, today announced that the company was selected by the Stanford-affiliated…
Read More

RenovoRx Receives CE Mark for RenovoCath™

RenovoRx, a leading developer of innovative solutions for targeted delivery of fluids to selected sites in the peripheral vascular system, today announced that the company achieved the CE Mark for…
Read More

First In-Human Use of RenovoCath™ Catheter

RenovoRx today announced the first in-human use of the RenovoCath™ catheter. RenovoRx is a leading developer of innovative solutions for targeted delivery of fluids, including therapeutic agents, to selected sites…
Read More

RenovoRx Achieves ISO 13485 Certification

Menlo Park, CA (March 2, 2015)–RenovoRx, a leading developer of innovative solutions for targeted delivery of fluids to selected sites in the vascular system,today announced that it has achieved ISO…
Read More

RenovoRx Patent Issued

Menlo Park, CA (October 28, 2014) – RenovoRx, a leading developer of innovative solutions for the isolation of blood flow and delivery of fluids to selected sites in the vascular…
Read More
Injection directly into tumor ball

RenovoRx Named TiE50 2013 Winner

RenovoRx today announces that it has been chosen as a winner of the 2013 TiE50 Awards, a highly influential list of the most enterprising startup companies across five verticals: Internet, Software, Mobile, Life Sciences, and Energy.

Read More
Injection directly into tumor ball

RenovoRx Featured by START-UP

RenovoRx is featured in the February 2013 issue of START-UP, an Elsevier Business Intelligence publication of in-depth profiles of leading-edge companies and technologies.

Read More

* Individual results may vary.

Menu